Fidelity Investments’s Protara Therapeutics TARA Stock Holding History

Fidelity Investments’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	68,200 +11,105	+19%	+$52.8K	﹤0.01%	3549
2026 Q1	$297K	Buy	57,095 +56,212	+6,366%	+$333K	﹤0.01%	3327
2025 Q4	$4.71K	Buy	883 +790	+849%	+$4.39K	﹤0.01%	4899
2025 Q3	$405	Buy	+93	New	+$301	﹤0.01%	5101
2023 Q3	–	Sell	-9	Closed	-$23	–	5507
2023 Q2	$23	Buy	+9	New	+$27	﹤0.01%	5150
2016 Q4	–	Sell	-3,936	Closed	-$1.47M	–	2709
2016 Q3	$1.47M	Hold	3,936	–	–	﹤0.01%	2413
2016 Q2	$1.26M	Sell	3,936 -11,558	-75%	-$3.46M	﹤0.01%	2446
2016 Q1	$4.8M	Sell	15,494 -5,756	-27%	-$1.86M	﹤0.01%	2173
2015 Q4	$13.2M	Hold	21,250	–	–	﹤0.01%	1868
2015 Q3	$11.8M	Hold	21,250	–	–	﹤0.01%	1886
2015 Q2	$15.2M	Hold	21,250	–	–	﹤0.01%	1850
2015 Q1	$9.89M	Hold	21,250	–	–	﹤0.01%	2000
2014 Q4	$8.84M	Buy	+21,250	New	+$8.57M	﹤0.01%	2043

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Fidelity Investments's TARA Position: Q2 2026 in Review

Fidelity Investments increased its Protara Therapeutics (TARA) stake by 19% in Q2 2026, buying an estimated $52.8K and bringing the position to 68,200 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #3549.

Fidelity Investments first reported a position in TARA in Q4 2014 and has held it in 13 quarters since. The position peaked at $15.2M in Q2 2015. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

Fidelity Investments held 68,200 shares of Protara Therapeutics worth $261K as of Q2 2026.
Fidelity Investments bought 11,105 Protara Therapeutics shares in Q2 2026, an estimated $52.8K.
Protara Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3549 holding.
Fidelity Investments first reported a position in Protara Therapeutics in Q4 2014 and has held it in 13 quarters since.
Fidelity Investments's Protara Therapeutics position peaked at $15.2M in Q2 2015.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.